Curis, Inc.

Curis Opens Eleven Clinical Sites for Phase 2 TakeAim CLL Study of Emavusertib–Zanubrutinib Combination

- Curis has activated eleven clinical sites for patient enrollment in its Phase 2 TakeAim CLL study evaluating emavusertib combined with zanubrutinib in chronic lymphocytic leukemia. - The company reaffirmed guidance that the initial five patients will be dosed by the end of July 2026, with initial data expected in December 2026. - The combination strategy targets dual blockade of NF-kB, a key driver of CLL, by pairing an IRAK4/FLT3 inhibitor with a BTK inhibitor. - Stockholders approved a reverse stock split at a ratio between 1-for-5 and 1-for-25 to help the company regain compliance with Nasdaq's $1.00 bid price rule.